Home / Health / Narcolepsy Drug Orzeyful Now Available in US
Narcolepsy Drug Orzeyful Now Available in US
12 Nov
Summary
- Orzeyful, a new narcolepsy pill, is now available in the U.S.
- The drug targets the underlying cause by addressing orexin signaling loss.
- Approximately 120,000 people in the U.S. are affected by narcolepsy type 1.
Takeda announced that Orzeyful, the first medication designed to address the fundamental cause of narcolepsy, is now accessible in the United States. This availability follows the Drug Enforcement Administration's decision to classify Orzeyful as a Schedule IV controlled substance, indicating a low potential for abuse and dependence. The U.S. Food and Drug Administration had previously approved the treatment in August for narcolepsy type 1.
Orzeyful functions by targeting the loss of orexin signaling, which is central to narcolepsy type 1. This rare disorder affects around 120,000 people in the U.S. and is characterized by excessive daytime sleepiness and sudden muscle tone loss. The pill, taken twice daily, aims to improve patients' ability to remain awake and significantly reduce cataplexy episodes.
